Cathie Wood's ARK Invest has significantly increased its stake in Intellia Therapeutics, signaling a strong vote of confidence in the biotech company's potential. On October 18, 2024, ARK purchased 161,792 shares of Intellia, amounting to approximately $3.39 million, which were spread across its ARKK and ARKG ETFs, as reported by Investing.com.
Continuing to bolster its position, ARK bought an additional 216,200 shares on October 24, 2024. Further expanding its investment, ARK added 218,758 more shares on December 20, totaling around $2.64 million, according to information from Investing.com and Nasdaq.com.
These purchases demonstrate ARK's strategic focus on companies with promising innovations in gene-editing technologies. Through these investments, ARK underscores its belief in Intellia's potential to make breakthroughs in addressing significant medical challenges.